Depression News

Researchers found positive associations between depressive features and self-stigma for those with substance use disorders, with the pull to self-stigma likely stronger than in the reverse, per a study published in BMC Psychiatry.

Resilience and organizational support protected against burnout, while social support and resilience led to better mental health outcomes among health care workers a year after the COVID-19 pandemic.

According to results of a recent poll, 37% of Americans rated their mental health as “fair” or “poor,” up from 31% a year ago, with 26% reporting that they anticipate experiencing more stress as the new year begins, up from 20% a year ago.

Factors for risk for rehospitalization for those with psychiatric disorders included suicidal ideation, suicide attempt, previous hospitalization and longer stay in hospital, according to a study published in BMC Psychiatry.

People experiencing persistent post-concussion symptoms were at a higher risk for depressive symptoms, researchers reported in JAMA Network Open.

A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003for treatment-resistant depression.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.

A new national telehealth program called Crisis Care has been created to treat individuals with elevated suicide risk, a release from Brightside Health stated.

The FDA has granted Vistagen fast track designation for PH10, a nasal spray for the treatment of major depressive disorder, according to a company press release.

Telehealth interventions were as effective as in-person treatment for reducing anxiety and depressive symptoms, according to data published in BMC Psychiatry.